In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck KGAA forms IBS spin-out Tioga Pharmaceuticals

Executive Summary

Merck KGAA has spun out Tioga Pharmaceuticals, a new company formed to further develop Merck's asimadoline for irritable bowel syndrome (IBS). Tioga raised an undisclosed amount in its Series A financing (including an investment by Forward Ventures), and is already planning to raise additional funds.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Spin-Off

Related Companies